Research & Development

Patients & Caregivers

Investors & News

Regulation Kits

Pipeline & Technologies

ARIAD Pipeline

Technologies

SUCCEED: Landmark Global Phase 3 Trial Now Enrolling! Deforolimus AP24534 - a novel multi-targeted kinase inhibitor Discovery Programs Publications Pipeline & Technologies

Clinical Trials in Oncology

>Now Enrolling: Phase 3 trial of oral deforolimus in patients with metastatic sarcomas
SUCCEED Trial >

>Learn More About:

In the News

05/07/2008
ARIAD Reports First Quarter 2008 Financial Results

05/02/2008
ARIAD to Participate at the Leerink Swann Cancer Roundtable Conference

04/30/2008
ARIAD to Webcast Conference Call on First Quarter 2008 Financial Results

04/15/2008
ARIAD Presents Preclinical Deforolimus Data at American Association for Cancer Research Meeting in Support of Clinical Initiatives

04/08/2008
Preclinical Data on ARIAD's Novel Investigational mTOR Inhibitor, Deforolimus, to Be Presented at the AACR Annual Meeting

03/13/2008
ARIAD to Webcast Presentation at the Lehman Brothers 11th Annual Global Healthcare Conference

©2008 ARIAD Pharmaceuticals, Inc.

Terms and Conditions Privacy Policy Safe Harbor Map & Directions